Sort   by:  
 Page size 
TranscriptomicsAdult ALL (Acute Lymphoblastic Leukemia)
A set of 37 BCR-ABL positive (21 and 16 of which expressed p185 and p210, respectively) and 17 BCR-ABL negative adult ALL specimens from the ECOG/MRC intergroup study E2993. Gene expression profiling was performed using the 3DNA Array 900 Expression Array Detection Kit (Genisphere, Hatfield, PA), ac...
ORGANISM(S): Homo sapiens 
2007-07-14 | E-GEOD-5314 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human BCR-ABL positive and negative adult Acute Lymphoblastic Leukemia samples
A set of 37 BCR-ABL positive (21 and 16 of which expressed p185 and p210, respectively) and 17 BCR-ABL negative adult ALL specimens from MRC UKALLXII/ECOG E2993 intergroup study. Gene expression profiling was performed using the 3DNA Array 900 Expression Array Detection Kit (Genisphere, Hatfield, PA...
ORGANISM(S): Homo sapiens 
2007-05-23 | E-SMDB-3750 | biostudies-arrayexpress
UnknownEfficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Not available
S-EPMC5559902 | biostudies-literature
UnknownPhosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Not available
S-EPMC5920739 | biostudies-literature
Genomicsena-DATASET-MGH-10-02-2015-15:17:58:985-1 - samples
DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. For WE sequencing we user Hybrid capture (Nimblegen version 3.0) of the lymph node and lung metastases, primary tumour and spleen normal; we generated ~1...
EGAD00001001252 | EGA
Genomicsena-DATASET-MGH-10-02-2015-15:19:45:352-2 - samples
DNA was derived from the primary tumour, lung metastasis, and peri-aortic lymph node metastasis. DNA from the spleen was used as a normal control. WG sequencing produced ~30-fold (primary tumour, spleen normal)-50-fold (lung metastasis) coverage
EGAD00001001253 | EGA
GenomicsTherapeutic Resistance to PI3K-alpha Inhibitors
We have studied the tumor genomic evolution in a patient with metastatic breast cancer bearing an activating PIK3CA mutation. The patient was treated with the PI3Kα inhibitor BYL719 and achieved a lasting clinical response on BYL719, but eventually progressed to treatment and died shortly thereafter...
EGAS00001000991 | EGA
GenomicsMemorial Sloan Kettering Cancer Center - Human Oncology & Pathogenesis Program (HOOP) - Data Access Committee
Data Access Committee EGAC00001000305
EGAC00001000305 | EGA
TranscriptomicsAXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Phosphoinositide-3-kinase (PI3K)-α inhibitors are clinically active in squamous carcinoma (SCC) of the head and neck (H&N) bearing mutations or amplification of PIK3CA. We aimed to identify potential mechanism of resistance and have observed that SCCs cells overcome the antitumor effects of the PI3K...
ORGANISM(S): Homo sapiens 
2015-04-12 | E-GEOD-61515 | biostudies-arrayexpress
Sort   by:  
 Page size